DK3662932T3 - Anti-cgrp-sammensætninger og anvendelse deraf - Google Patents

Anti-cgrp-sammensætninger og anvendelse deraf Download PDF

Info

Publication number: DK3662932T3
Authority: DK; Denmark
Prior art keywords: application; cgrp compositions; cgrp; compositions
Prior art date: 2011-05-20

Application number

DK19215303.9T

Other languages

English (en)

Inventor

Benjamin H Dutzar

Jens J Billgren

John A Latham

Danielle M Mitchell

Patricia Dianne Mcneill

Nicole M Janson

Maria-Cristina Loomis

Brian Robert Kovacevich

Leon F Garcia-Martinez

Katie Olson

Original Assignee

H Lundbeck As

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-05-20

Filing date

2012-05-21

Publication date

2021-05-17

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47175055&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3662932(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-05-21 Application filed by H Lundbeck As filed Critical H Lundbeck As

2021-05-17 Application granted granted Critical

2021-05-17 Publication of DK3662932T3 publication Critical patent/DK3662932T3/da

Links

XAZKFISIRYLAEE-UHFFFAOYSA-N CC1CC(C)CC1 Chemical compound CC1CC(C)CC1 XAZKFISIRYLAEE-UHFFFAOYSA-N 0.000 description 2

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Immunology (AREA)
Genetics & Genomics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Endocrinology (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Emergency Medicine (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
General Engineering & Computer Science (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DK19215303.9T 2011-05-20 2012-05-21 Anti-cgrp-sammensætninger og anvendelse deraf DK3662932T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161488660P	2011-05-20	2011-05-20
EP18203518.8A EP3495392B1 (en)	2011-05-20	2012-05-21	Anti-cgrp compositions and use thereof

Publications (1)

Publication Number	Publication Date
DK3662932T3 true DK3662932T3 (da)	2021-05-17

Family

ID=47175055

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
DK19215303.9T DK3662932T3 (da)	2011-05-20	2012-05-21	Anti-cgrp-sammensætninger og anvendelse deraf
DK18203518.8T DK3495392T3 (da)	2011-05-20	2012-05-21	Anti-cgrp-sammensætninger og anvendelse deraf
DK12789693.4T DK2710039T3 (da)	2011-05-20	2012-05-21	Anti-cgrp-sammensætninger og anvendelse deraf

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
DK18203518.8T DK3495392T3 (da)	2011-05-20	2012-05-21	Anti-cgrp-sammensætninger og anvendelse deraf
DK12789693.4T DK2710039T3 (da)	2011-05-20	2012-05-21	Anti-cgrp-sammensætninger og anvendelse deraf

Country Status (38)

Country	Link
US (10)	US9745373B2 (da)
EP (5)	EP3662932B1 (da)
JP (3)	JP6282584B2 (da)
KR (1)	KR102128627B1 (da)
CN (5)	CN108424452B (da)
AP (1)	AP2013007259A0 (da)
AR (3)	AR086516A1 (da)
AU (3)	AU2012258966C1 (da)
BR (2)	BR112013029932A2 (da)
CA (3)	CA2836649C (da)
CL (3)	CL2013003336A1 (da)
CO (1)	CO6870005A2 (da)
CY (2)	CY1124209T1 (da)
DK (3)	DK3662932T3 (da)
EA (3)	EA031065B1 (da)
ES (3)	ES2715001T3 (da)
FR (1)	FR22C1032I2 (da)
HR (3)	HRP20190640T1 (da)
HU (4)	HUE055505T2 (da)
IL (4)	IL229431B (da)
LT (4)	LT3662932T (da)
LU (1)	LUC00270I2 (da)
MX (3)	MX370749B (da)
NL (1)	NL301181I2 (da)
NO (1)	NO2022029I1 (da)
NZ (1)	NZ733060A (da)
PE (2)	PE20141787A1 (da)
PH (2)	PH12013502405B1 (da)
PL (3)	PL3662932T3 (da)
PT (3)	PT3662932T (da)
RS (3)	RS61793B1 (da)
SG (2)	SG10201604040PA (da)
SI (3)	SI3495392T1 (da)
SM (3)	SMT201900293T1 (da)
TR (1)	TR201904088T4 (da)
TW (4)	TWI719869B (da)
WO (1)	WO2012162243A2 (da)
ZA (1)	ZA201308637B (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5123197B2 (ja)	2005-11-14	2013-01-16	ライナットニューロサイエンスコーポレイション	カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
JP5537441B2 (ja)	2008-03-04	2014-07-02	ファイザー・リミテッド	慢性疼痛を治療する方法
CN103957935B (zh)	2011-05-20	2018-04-03	奥尔德生物控股有限责任公司	抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
EP3662932B1 (en) *	2011-05-20	2021-04-07	H. Lundbeck A/S	Anti-cgrp compositions and use thereof
NZ732970A (en)	2011-05-20	2022-08-26	H Lundbeck As	Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
ES2834113T3 (es) *	2013-03-15	2021-06-16	H Lundbeck As	Purificación de anticuerpos y monitorización de la pureza
KR102476907B1 (ko) *	2013-07-03	2022-12-13	하. 룬드벡 아크티에셀스카브	항-ｃｇｒｐ 항체를 사용하는 글루코오스 대사의 조절
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
HRP20240159T1 (hr)	2014-03-21	2024-04-12	Teva Pharmaceuticals International Gmbh	Antagonistička protutijela usmjerena protiv peptida povezanog s genom kalcitonina i postupci koji ih koriste
US10556945B2 (en)	2014-03-21	2020-02-11	Teva Pharmaceuticals International Gmbh	Antagonist antibodies directed against calcitonin gene-related peptide and methods using same
JP6752223B2 (ja) *	2015-04-16	2020-09-09	アルダー・バイオファーマシューティカルズ・インコーポレーテッド	羞明を処置、予防、または阻害するための抗ｐａｃａｐ抗体及びそれらの抗原結合性断片の使用
TWI799849B (zh)	2015-04-24	2023-04-21	美商安美基公司	治療或預防偏頭痛之方法
AR104847A1 (es) *	2015-06-17	2017-08-16	Lilly Co Eli	Formulación de anticuerpo anti-cgrp
ES2846878T3 (es) *	2015-09-24	2021-07-30	Teva Pharmaceuticals Int Gmbh	Prevenir, tratar y reducir el dolor de cabeza post-traumático (persistente)
TW201725212A (zh)	2015-12-10	2017-07-16	第一三共股份有限公司	特異性於降鈣素基因相關胜肽的新穎蛋白
AU2017211043A1 (en) *	2016-01-28	2018-06-14	Eli Lilly And Company	CGRP antibodies and uses thereof
EP3411066A1 (en)	2016-02-01	2018-12-12	Eli Lilly and Company	Parathyroid hormone anti-rankl antibody fusion compounds
CA3020839A1 (en)	2016-04-15	2017-10-19	Alder Biopharmaceuticals, Inc.	Anti-pacap antibodies and uses thereof
MX2019003338A (es)	2016-09-23	2019-09-26	Teva Pharmaceuticals Int Gmbh	Tratamiento de cefalea en racimos.
KR20220031944A (ko)	2016-09-23	2022-03-14	테바 파마슈티컬스 인터내셔널 게엠베하	불응성 편두통의 치료
WO2018160897A1 (en) *	2017-03-02	2018-09-07	Beth Israel Deaconess Medical Center, Inc.	Preventing post-ictal headaches
JP2020517644A (ja) *	2017-04-19	2020-06-18	マンセル、ジョン	疼痛障害の治療のための組成物および方法
US10738110B2 (en)	2018-01-12	2020-08-11	Amgen Inc.	PAC1 antibodies and uses thereof
US11274158B2 (en) *	2018-01-30	2022-03-15	Flagship Pioneering Innovations V, Inc.	Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators
JP2021518748A (ja) *	2018-02-23	2021-08-05	アールイーエムディーバイオセラピューティクス，インコーポレイテッドＲＥＭＤＢｉｏｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ	カルシトニン遺伝子関連ペプチド（ｃｇｒｐ）アンタゴニスト抗体
WO2019231800A1 (en) *	2018-05-31	2019-12-05	Eli Lilly And Company	Anti-cgrp antibodies for treating menstrual-related migraines
US10899826B1 (en) *	2018-09-13	2021-01-26	Teva Pharmaceuticals International Gmbh	Pharmaceutical compositions for an anti-CGRP antagonist antibody
EP3674418A1 (en) *	2018-12-26	2020-07-01	Life Length S.L.	Method for measuring telomere associated variables and uses thereof for the diagnosis and/or prognosis of telomeric-associated diseases
US11639380B2 (en) *	2019-01-08	2023-05-02	H. Lundbeck A/S	Acute treatment and rapid treatment of headache using anti-CGRP antibodies
MX2021008268A (es) *	2019-01-08	2021-08-05	H Lundbeck As	Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
WO2020175936A1 (ko) *	2019-02-28	2020-09-03	단디바이오사이언스 주식회사	항균활성을 갖는 폴리펩타이드, 이를 포함하는 패혈증 예방 또는 치료용 조성물, 및 항균용 조성물
BR112020027063A2 (pt) *	2019-05-02	2021-11-16	H Lundbeck As	Tratamento de dor de cabeça com uso de anticorpos anti-cgrp
WO2020239014A1 (zh) *	2019-05-30	2020-12-03	山东博安生物技术有限公司	抗cgrp抗体及其应用
CA3077973A1 (en)	2020-04-06	2021-10-06	H. Lundbeck A/S	Treatment of most bothersome symptom (mbs) associated with migraine using anti-cgrp antibodies
JP2024509165A (ja)	2021-03-02	2024-02-29	シージーアールピーダイアグノスティクスゲーエムベーハー	片頭痛の治療及び／又は発生の低減
WO2023026205A1 (en)	2021-08-24	2023-03-02	Cgrp Diagnostics Gmbh	Preventative treatment of migraine
JP2024532143A (ja)	2021-08-27	2024-09-05	ハー・ルンドベック・アクチエゼルスカベット	抗ｃｇｒｐ抗体を使用した群発頭痛の治療
US20250186580A1 (en)	2022-02-28	2025-06-12	Tridem Bioscience Gmbh & Co Kg	A CONJUGATE COMPRISING AT LEAST A ß-GLUCAN
EP4570913A1 (en) *	2022-08-11	2025-06-18	Shanghai Junshi Biosciences Co., Ltd.	Anti-cgrp antibody and use
CN115960227A (zh) *	2022-11-08	2023-04-14	河南赛诺特生物技术有限公司	一种抗人msh2的单克隆抗体及其制备方法和应用
IT202300010371A1 (it) *	2023-05-23	2024-11-23	Alberto Chiarugi	Inibitori della crescita tumorale
CN120899912A (zh) *	2024-05-07	2025-11-07	中国人民解放军军事科学院军事医学研究院	一种治疗自身免疫性疾病的方法和应用
CN118271438B (zh) *	2024-05-27	2024-08-30	上海宏成药业有限公司	抗cgrp抗体或其抗原结合片段及其用途
US20260001942A1 (en)	2024-06-21	2026-01-01	H. Lundbeck A/S	Treatment of headache disorders and/or psychiatric symptoms using anti-cgrp antibodies, and compositions and methods related thereto

Family Cites Families (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3662333A (en)	1970-09-08	1972-05-09	Bendix Corp	Hydraulic accumulator charge detector and indicating system
US4179337A (en)	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
JPS5123197A (ja)	1974-08-21	1976-02-24	Hitachi Ltd	Purosesugasukuromatogurafuno ondoseigyohoshiki
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
DE3484377D1 (de) *	1983-06-15	1991-05-08	Celltech Ltd	Peptide, pharmazeutische zusammensetzungen, gene, vektoren, wirtorganismen, verfahren zu deren herstellung und diagnostische reagenzien.
JPS62129297A (ja)	1985-08-09	1987-06-11	Toyo Jozo Co Ltd	カルシトニン遺伝子関連ペプチド誘導体
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
AU600575B2 (en)	1987-03-18	1990-08-16	Sb2, Inc.	Altered antibodies
GB8725529D0 (en)	1987-10-30	1987-12-02	Delta Biotechnology Ltd	Polypeptides
US5364841A (en)	1988-01-11	1994-11-15	Amylin Pharmaceuticals, Inc.	Treatment of obesity and essential hypertension and related disorders
US5266561A (en)	1988-01-11	1993-11-30	Amylin Pharmaceuticals, Inc.	Treatment of type 2 diabetes mellitus
JP2989002B2 (ja)	1988-12-22	1999-12-13	キリン―アムジエン・インコーポレーテツド	化学修飾顆粒球コロニー刺激因子
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5116964A (en)	1989-02-23	1992-05-26	Genentech, Inc.	Hybrid immunoglobulins
US5766883A (en)	1989-04-29	1998-06-16	Delta Biotechnology Limited	Polypeptides
FR2650598B1 (fr)	1989-08-03	1994-06-03	Rhone Poulenc Sante	Derives de l'albumine a fonction therapeutique
US5859205A (en)	1989-12-21	1999-01-12	Celltech Limited	Humanised antibodies
WO1992002551A1 (en)	1990-08-02	1992-02-20	B.R. Centre Limited	Methods for the production of proteins with a desired function
FR2669336B1 (fr)	1990-11-20	1993-01-22	Adir	Nouveaux derives d'oxazolo pyridines, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
WO1994004679A1 (en)	1991-06-14	1994-03-03	Genentech, Inc.	Method for making humanized antibodies
EP0940468A1 (en)	1991-06-14	1999-09-08	Genentech, Inc.	Humanized antibody variable domain
FR2686899B1 (fr)	1992-01-31	1995-09-01	Rhone Poulenc Rorer Sa	Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
DE4227454C1 (de) *	1992-08-19	1994-02-03	Henning Berlin Gmbh	Verfahren zur Früherkennung, zur Erkennung des Schweregrads sowie zur therapiebegleitenden Verlaufsbeurteilung einer Sepsis sowie Mittel zur Durchführung des Verfahrens
US5604260A (en)	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
US5409944A (en)	1993-03-12	1995-04-25	Merck Frosst Canada, Inc.	Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
WO1994021293A1 (en)	1993-03-19	1994-09-29	Duke University	Method of treatment of tumors with an antibody binding to tenascin
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5436265A (en)	1993-11-12	1995-07-25	Merck Frosst Canada, Inc.	1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5643575A (en)	1993-10-27	1997-07-01	Enzon, Inc.	Non-antigenic branched polymer conjugates
US5475995A (en)	1994-05-16	1995-12-19	Livingston; George G.	Truck spare tire locking rod
US5616601A (en)	1994-07-28	1997-04-01	Gd Searle & Co	1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation
CA2195557C (en)	1994-08-12	2006-10-17	Shui-On Leung	Immunoconjugates and humanized antibodies specific for b-cell lymphoma and leukemia cells
ATE265466T1 (de)	1994-08-16	2004-05-15	Human Genome Sciences Inc	Calcitoninrezeptor
US5521213A (en)	1994-08-29	1996-05-28	Merck Frosst Canada, Inc.	Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2
US5593994A (en)	1994-09-29	1997-01-14	The Dupont Merck Pharmaceutical Company	Prostaglandin synthase inhibitors
US5552422A (en)	1995-01-11	1996-09-03	Merck Frosst Canada, Inc.	Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents
FR2732221B1 (fr)	1995-03-28	1997-04-25	Oreal	Utilisation d'un antagoniste de cgrp pour traiter les rougeurs cutanees d'origine neurogene et composition obtenue
US5510368A (en)	1995-05-22	1996-04-23	Merck Frosst Canada, Inc.	N-benzyl-3-indoleacetic acids as antiinflammatory drugs
US5639780A (en)	1995-05-22	1997-06-17	Merck Frosst Canada, Inc.	N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5604253A (en)	1995-05-22	1997-02-18	Merck Frosst Canada, Inc.	N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors
WO1997009046A1 (en)	1995-09-05	1997-03-13	Smithkline Beecham Corporation	Compounds and methods
US5710024A (en) *	1996-07-23	1998-01-20	Smithkline Beecham Corporation	Polynucleotides that encode the calcitonin gene-related peptide receptor coponent factor (HOUNDC44)
EP0934068A1 (en)	1996-09-09	1999-08-11	Smithkline Beecham Corporation	Compounds and methods
BR9712023A (pt)	1996-09-10	1999-08-31	Thomae Gmbh Dr K	Aminoácidos derivados, medicamentos contendo esses compostos e processos para a sua preparação.
US6653104B2 (en)	1996-10-17	2003-11-25	Immunomedics, Inc.	Immunotoxins, comprising an internalizing antibody, directed against malignant and normal cells
WO1998056779A1 (en)	1997-06-13	1998-12-17	Smithkline Beecham Corporation	4-sulfinyl benzamides as calcitonin gene-related peptide receptor antagonists
US6956107B2 (en)	1998-02-20	2005-10-18	Tanox, Inc.	Inhibitors of complement activation
AU6211499A (en)	1998-09-30	2000-04-17	Merck & Co., Inc.	Benzimidazolinyl piperidines as cgrp ligands
AU1219000A (en)	1998-10-22	2000-05-08	Regents Of The University Of California, The	Functionally assembled antigen-specific intact recombinant antibody and a methodfor production thereof
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP1031350A1 (en)	1999-02-23	2000-08-30	Warner-Lambert Company	Use of a gabapentin-analog for the manufacture of a medicament for preventing and treating visceral pain
US6313097B1 (en)	1999-03-02	2001-11-06	Boehringer Ingelheim Pharma Kg	Antagonists of calcitonin gene-related peptide
US6521609B1 (en)	1999-08-10	2003-02-18	Boehringer Ingelheim Pharma Kg	Use of CGRP antagonists and CGRP release inhibitors for combating menopausal hot flushes
TR200200797T2 (tr)	1999-09-25	2002-10-21	University Of Iowa Research Foundation	İmmünostimülatör nükleik asitler
WO2001064751A2 (en)	2000-03-01	2001-09-07	Medimmune, Inc.	High potency recombinant antibodies and method for producing them
US6406863B1 (en)	2000-06-23	2002-06-18	Genetastix Corporation	High throughput generation and screening of fully human antibody repertoire in yeast
US20020162125A1 (en)	2001-03-06	2002-10-31	Anne-Marie Salmon	Methods and compositions for the modulation of neurogenic inflammatory pain and physical opiate withdrawal
US20030181462A1 (en)	2001-08-17	2003-09-25	Boehringer Ingelheim Pharma Kg	Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine
CN1617737A (zh)	2001-11-26	2005-05-18	普罗特米克斯公司	用于使哺乳动物组织中的脂质水平正常化的组合物和方法
CN1326879C (zh)	2002-03-29	2007-07-18	先灵公司	人源抗白细胞介素5单克隆抗体及其制备方法和包含这些抗体的组合物
EP1501929B1 (de)	2002-05-06	2013-03-27	Noxxon Pharma AG	Cgrp bindende nukleinsäuren
US20040110170A1 (en)	2002-05-18	2004-06-10	The Regents Of The University Of California	Cloning and characterization of calcitonin gene related peptide receptors
US7345065B2 (en)	2002-05-21	2008-03-18	Allergan, Inc.	Methods and compositions for alleviating pain
MXPA04011960A (es)	2002-06-05	2005-03-31	Squibb Bristol Myers Co	Antagonistas de receptores de peptidos relacionados con el gen de calcitonina.
EP1517921B1 (en)	2002-06-28	2006-06-07	Domantis Limited	Dual specific ligands with increased serum half-life
PL375536A1 (en) *	2002-08-12	2005-11-28	Birkir Sveinsson	Use of cgrp antagonist compounds for treatment of psoriasis
UA80447C2 (en)	2002-10-08	2007-09-25		Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
DE10250082A1 (de)	2002-10-25	2004-05-13	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7285269B2 (en)	2002-12-02	2007-10-23	Amgen Fremont, Inc.	Antibodies directed to tumor necrosis factor
CN102746399B (zh)	2002-12-24	2016-03-02	里纳特神经系统学公司	抗ngf抗体及其使用方法
ATE516803T1 (de)	2003-03-14	2011-08-15	Merck Sharp & Dohme	Aryl-spirohydantoin-cgrp-rezeptor-antagonisten
CA2518852A1 (en)	2003-03-14	2004-09-30	Merck & Co., Inc.	Monocyclic anilide spirohydantoin cgrp receptor antagonists
ATE535514T1 (de)	2003-03-14	2011-12-15	Merck Sharp & Dohme	Carboxamid-spirohydantoin-cgrp-rezeptor- antagonisten
EP1606286B1 (en)	2003-03-14	2011-05-11	Merck Sharp & Dohme Corp.	Benodiazepine spirohydantoin cgrp receptor antagonists
WO2004082605A2 (en)	2003-03-14	2004-09-30	Merck & Co. Inc.	Bicyclic anilide spirohydantoin cgrp receptor antagonists
CA2522024A1 (en)	2003-04-15	2004-10-28	Merck & Co., Inc.	Cgrp receptor antagonists
JO2355B1 (en)	2003-04-15	2006-12-12	ميرك شارب اند دوم كوربوريشن	Hereditary calcitonin polypeptide receptor antagonists
WO2004097421A2 (en)	2003-04-29	2004-11-11	Bayer Healthcare Ag	Diagnostics and therapeutics for diseases associated with calcitonin receptor-like receptor (calcrl)
AU2004259675A1 (en)	2003-07-15	2005-02-03	Merck & Co., Inc.	Hydroxypyridine CGRP receptor antagonists
CN101979650B (zh)	2003-10-22	2015-09-16	凯克研究生院	使用单倍体交配策略在酵母中合成异聚多亚基多肽的方法
US20080070239A1 (en)	2003-10-29	2008-03-20	University Of Rochester	Detection of neureopeptides associated with pelvic pain disorders and uses thereof
JP2007517911A (ja)	2004-01-13	2007-07-05	バソジェニックスファーマシューティカルズ，インコーポレイテッド	心臓血管の適応症および腎臓の適応症に対してｃｇｒｐを使用する方法
DE102004015723A1 (de)	2004-03-29	2005-10-20	Boehringer Ingelheim Pharma	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE102004018794A1 (de)	2004-04-15	2005-10-27	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Ausgewählte CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
US7279471B2 (en)	2004-04-15	2007-10-09	Boehringer Ingelheim International Gmbh	Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions
TWI432196B (zh)	2005-01-18	2014-04-01	Euro Celtique Sa	內臟痛的治療
EP1770091A1 (de)	2005-09-29	2007-04-04	Boehringer Ingelheim Pharma GmbH & Co. KG	CGRP-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ITRM20050290A1 (it)	2005-06-07	2006-12-08	Lay Line Genomics Spa	Uso di molecole in grado di inibire il legame tra ngf e il suo recettore trka come analgesici ad effetto prolungato.
EP1928452A4 (en)	2005-08-25	2010-09-01	Wex Medical Ltd	USE OF SODIUM CHANNEL BLOCKS FOR THE TREATMENT OF VISCERAL PAIN OR PAIN THROUGH CANCER TREATMENT
US8168592B2 (en)	2005-10-21	2012-05-01	Amgen Inc.	CGRP peptide antagonists and conjugates
JP5123197B2 (ja) *	2005-11-14	2013-01-16	ライナットニューロサイエンスコーポレイション	カルシトニン遺伝子関連ペプチドに対するアンタゴニスト抗体およびその使用方法
US20070108378A1 (en)	2005-11-14	2007-05-17	Toru Terabayashi	High pressure optical cell for a downhole optical fluid analyzer
DE602006019304D1 (de)	2005-11-18	2011-02-10	Merck Sharp & Dohme	Spirohydantoin-aryl-cgrp-rezeptorantagonisten
WO2007076336A1 (en) *	2005-12-22	2007-07-05	Eli Lilly And Company	Treatment of migraine with anti-cgrp antibodies
US9074352B2 (en)	2006-03-27	2015-07-07	John R. Ramun	Universal control scheme for mobile hydraulic equipment and method for achieving the same
DK2021463T3 (da)	2006-05-19	2017-01-16	Alder Biopharmaceuticals Inc	Dyrkningsfremgangsmåde til at opnå en klonet population af antigen-specifikke B-celler
JP2009539799A (ja)	2006-06-08	2009-11-19	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｃｇｒｐ拮抗薬
CN101516875A (zh)	2006-07-21	2009-08-26	沃泰克斯药物股份有限公司	Cgrp受体拮抗剂
US8075902B2 (en) *	2007-01-03	2011-12-13	Michael Powell	Diagnosis and treatment of cancer related to human dormancy
TW201531484A (zh)	2007-05-21	2015-08-16	Alder Biopharmaceuticals Inc	抗ＴＮＦ-α之抗體及其用途
KR101741731B1 (ko)	2007-05-21	2017-05-30	앨더바이오 홀딩스 엘엘씨	Ｉｌ-６에 대한 항체 및 이의 용도
KR20170036814A (ko)	2007-05-21	2017-04-03	앨더바이오 홀딩스 엘엘씨	신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
GB0725103D0 (en) *	2007-12-21	2008-01-30	Glaxo Group Ltd	Novel compounds
JP5537441B2 (ja)	2008-03-04	2014-07-02	ファイザー・リミテッド	慢性疼痛を治療する方法
DK2265288T3 (da) *	2008-03-04	2016-06-06	Labrys Biologics Inc	Fremgangsmåder til behandling af inflammatorisk smerte
JO3382B1 (ar)	2008-12-23	2019-03-13	Amgen Inc	أجسام مضادة ترتبط مع مستقبل cgrp بشري
KR101519192B1 (ko) *	2009-08-28	2015-05-11	리나트 뉴로사이언스 코프.	칼시토닌 유전자-관련된 펩티드에 대해 지시된 길항제 항체의 투여에 의한 내장 통증의 치료 방법
AR081434A1 (es) *	2010-06-10	2012-08-29	Lilly Co Eli	Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
US11214610B2 (en) *	2010-12-01	2022-01-04	H. Lundbeck A/S	High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
CN103957935B (zh)	2011-05-20	2018-04-03	奥尔德生物控股有限责任公司	抗cgrp或抗cgrp‑r抗体或抗体片段用于治疗或预防慢性和急性形式的腹泻的用途
NZ732970A (en)	2011-05-20	2022-08-26	H Lundbeck As	Use of anti-cgrp antibodies and antibody fragments to prevent or inhibit photophobia or light aversion in subjects in need thereof, especially migraine sufferers
EP3662932B1 (en) *	2011-05-20	2021-04-07	H. Lundbeck A/S	Anti-cgrp compositions and use thereof
US20170114122A1 (en)	2015-10-23	2017-04-27	Alderbio Holdings Llc	Regulation of glucose metabolism using anti-cgrp antibodies
ES2846878T3 (es)	2015-09-24	2021-07-30	Teva Pharmaceuticals Int Gmbh	Prevenir, tratar y reducir el dolor de cabeza post-traumático (persistente)
WO2018160897A1 (en) *	2017-03-02	2018-09-07	Beth Israel Deaconess Medical Center, Inc.	Preventing post-ictal headaches
US11752099B2 (en) *	2017-03-27	2023-09-12	W. L. Gore & Associates, Inc.	Injectable and biodegradable polymer formulations for controlled release of bioactive agents
WO2018236873A1 (en) *	2017-06-19	2018-12-27	President And Fellows Of Harvard College	Methods and compositions for treating a microbial infection
TWI754772B (zh) *	2017-09-06	2022-02-11	美商美國禮來大藥廠	用於治療偏頭痛之拉米迪坦(lasmiditan)與cgrp拮抗劑之組合療法
MX2021008268A (es)	2019-01-08	2021-08-05	H Lundbeck As	Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
US11639380B2 (en) *	2019-01-08	2023-05-02	H. Lundbeck A/S	Acute treatment and rapid treatment of headache using anti-CGRP antibodies

2012
- 2012-05-21 EP EP19215303.9A patent/EP3662932B1/en active Active
- 2012-05-21 TW TW109110803A patent/TWI719869B/zh active
- 2012-05-21 EA EA201301295A patent/EA031065B1/ru unknown
- 2012-05-21 LT LTEP19215303.9T patent/LT3662932T/lt unknown
- 2012-05-21 TW TW107143050A patent/TWI692485B/zh active
- 2012-05-21 SI SI201231944T patent/SI3495392T1/sl unknown
- 2012-05-21 EP EP18203518.8A patent/EP3495392B1/en active Active
- 2012-05-21 PE PE2013002534A patent/PE20141787A1/es active IP Right Grant
- 2012-05-21 LT LTEP12789693.4T patent/LT2710039T/lt unknown
- 2012-05-21 LT LTEP18203518.8T patent/LT3495392T/lt unknown
- 2012-05-21 RS RS20210554A patent/RS61793B1/sr unknown
- 2012-05-21 CN CN201810269398.7A patent/CN108424452B/zh active Active
- 2012-05-21 EP EP21159270.4A patent/EP3875115A1/en active Pending
- 2012-05-21 AR ARP120101804A patent/AR086516A1/es active IP Right Grant
- 2012-05-21 CN CN201710917266.6A patent/CN107586338B/zh active Active
- 2012-05-21 DK DK19215303.9T patent/DK3662932T3/da active
- 2012-05-21 WO PCT/US2012/038844 patent/WO2012162243A2/en not_active Ceased
- 2012-05-21 PE PE2018000036A patent/PE20180502A1/es unknown
- 2012-05-21 EA EA201891284A patent/EA201891284A1/ru unknown
- 2012-05-21 EA EA201592042A patent/EA039905B1/ru unknown
- 2012-05-21 EP EP22178673.4A patent/EP4115905A1/en active Pending
- 2012-05-21 PH PH1/2013/502405A patent/PH12013502405B1/en unknown
- 2012-05-21 BR BR112013029932A patent/BR112013029932A2/pt not_active Application Discontinuation
- 2012-05-21 BR BR122022012930-7A patent/BR122022012930B1/pt active IP Right Grant
- 2012-05-21 EP EP12789693.4A patent/EP2710039B1/en active Active
- 2012-05-21 ES ES12789693T patent/ES2715001T3/es active Active
- 2012-05-21 SM SM20190293T patent/SMT201900293T1/it unknown
- 2012-05-21 SI SI201231586T patent/SI2710039T1/sl unknown
- 2012-05-21 SM SM20210526T patent/SMT202100526T1/it unknown
- 2012-05-21 CN CN201810269354.4A patent/CN108373502B/zh active Active
- 2012-05-21 NZ NZ733060A patent/NZ733060A/en unknown
- 2012-05-21 PT PT192153039T patent/PT3662932T/pt unknown
- 2012-05-21 TW TW101118029A patent/TWI646111B/zh active
- 2012-05-21 HR HRP20190640TT patent/HRP20190640T1/hr unknown
- 2012-05-21 CA CA2836649A patent/CA2836649C/en active Active
- 2012-05-21 JP JP2014512923A patent/JP6282584B2/ja active Active
- 2012-05-21 PL PL19215303T patent/PL3662932T3/pl unknown
- 2012-05-21 PL PL18203518T patent/PL3495392T3/pl unknown
- 2012-05-21 PT PT12789693T patent/PT2710039T/pt unknown
- 2012-05-21 ES ES18203518T patent/ES2893073T3/es active Active
- 2012-05-21 MX MX2013013535A patent/MX370749B/es active IP Right Grant
- 2012-05-21 AU AU2012258966A patent/AU2012258966C1/en active Active
- 2012-05-21 SI SI201231916T patent/SI3662932T1/sl unknown
- 2012-05-21 CA CA3080000A patent/CA3080000A1/en active Pending
- 2012-05-21 HU HUE18203518A patent/HUE055505T2/hu unknown
- 2012-05-21 TW TW106121803A patent/TWI685505B/zh active
- 2012-05-21 CA CA3079978A patent/CA3079978A1/en active Pending
- 2012-05-21 DK DK18203518.8T patent/DK3495392T3/da active
- 2012-05-21 RS RS20211095A patent/RS62306B1/sr unknown
- 2012-05-21 RS RS20190430A patent/RS58621B1/sr unknown
- 2012-05-21 PL PL12789693T patent/PL2710039T3/pl unknown
- 2012-05-21 KR KR1020137033843A patent/KR102128627B1/ko active Active
- 2012-05-21 SM SM20210274T patent/SMT202100274T1/it unknown
- 2012-05-21 CN CN201710902899.XA patent/CN107602700B/zh active Active
- 2012-05-21 SG SG10201604040PA patent/SG10201604040PA/en unknown
- 2012-05-21 PT PT182035188T patent/PT3495392T/pt unknown
- 2012-05-21 HU HUE12789693A patent/HUE044062T2/hu unknown
- 2012-05-21 US US13/476,465 patent/US9745373B2/en active Active
- 2012-05-21 CN CN201280035733.8A patent/CN103748111B/zh active Active
- 2012-05-21 SG SG2013084058A patent/SG194938A1/en unknown
- 2012-05-21 TR TR2019/04088T patent/TR201904088T4/tr unknown
- 2012-05-21 HU HUE19215303A patent/HUE054437T2/hu unknown
- 2012-05-21 ES ES19215303T patent/ES2873837T3/es active Active
- 2012-05-21 DK DK12789693.4T patent/DK2710039T3/da active
- 2012-05-21 AP AP2013007259A patent/AP2013007259A0/xx unknown
2013
- 2013-11-14 IL IL229431A patent/IL229431B/en active IP Right Grant
- 2013-11-18 ZA ZA2013/08637A patent/ZA201308637B/en unknown
- 2013-11-19 MX MX2019008185A patent/MX2019008185A/es unknown
- 2013-11-19 MX MX2019015745A patent/MX2019015745A/es unknown
- 2013-11-20 CL CL2013003336A patent/CL2013003336A1/es unknown
- 2013-11-22 CO CO13275276A patent/CO6870005A2/es unknown
2016
- 2016-09-06 US US15/257,562 patent/US10066009B2/en active Active
2017
- 2017-05-30 CL CL2017001379A patent/CL2017001379A1/es unknown
- 2017-06-08 AU AU2017203890A patent/AU2017203890B2/en active Active
- 2017-08-24 JP JP2017160778A patent/JP6527563B2/ja active Active
2018
- 2018-02-09 US US15/892,892 patent/US10208112B2/en active Active
- 2018-02-09 US US15/892,858 patent/US10214582B2/en active Active
- 2018-02-09 US US15/892,804 patent/US10179809B2/en active Active
- 2018-02-09 US US15/892,956 patent/US10189895B2/en active Active
- 2018-03-09 PH PH12018500521A patent/PH12018500521A1/en unknown
- 2018-05-30 CL CL2018001452A patent/CL2018001452A1/es unknown
- 2018-08-30 US US16/117,401 patent/US10533048B2/en active Active
- 2018-09-25 IL IL26192718A patent/IL261927B/en active IP Right Grant
2019
- 2019-01-15 US US16/248,284 patent/US11111289B2/en active Active
- 2019-05-09 JP JP2019088960A patent/JP6952736B2/ja active Active
- 2019-08-04 IL IL268464A patent/IL268464B/en active IP Right Grant
- 2019-09-06 AU AU2019226231A patent/AU2019226231B2/en active Active
- 2019-11-03 IL IL270382A patent/IL270382B/en active IP Right Grant
2020
- 2020-01-13 US US16/740,699 patent/US20210047391A1/en not_active Abandoned
- 2020-04-06 AR ARP200100966A patent/AR118605A2/es unknown
2021
- 2021-05-11 CY CY20211100403T patent/CY1124209T1/el unknown
- 2021-05-14 HR HRP20210777TT patent/HRP20210777T1/hr unknown
- 2021-09-02 HR HRP20211395TT patent/HRP20211395T1/hr unknown
- 2021-09-21 CY CY20211100830T patent/CY1124515T1/el unknown
- 2021-10-21 AR ARP210102914A patent/AR123876A2/es unknown
2022
- 2022-06-13 NL NL301181C patent/NL301181I2/nl unknown
- 2022-06-20 LT LTPA2022511C patent/LTC3495392I2/lt unknown
- 2022-06-22 HU HUS2200031C patent/HUS2200031I1/hu unknown
- 2022-06-29 FR FR22C1032C patent/FR22C1032I2/fr active Active
- 2022-06-30 LU LU00270C patent/LUC00270I2/fr unknown
- 2022-07-08 NO NO2022029C patent/NO2022029I1/no unknown
2023
- 2023-07-05 US US18/346,961 patent/US20240174738A1/en active Pending

Also Published As

Publication number	Publication date
BR112013029932A2 (pt)	2017-01-31
US20210047391A1 (en)	2021-02-18
IL229431B (en)	2018-10-31
JP6952736B2 (ja)	2021-10-20
JP2019150044A (ja)	2019-09-12
EA201891284A1 (ru)	2018-11-30
EP2710039B1 (en)	2019-01-09
LT3662932T (lt)	2021-06-10
HRP20190640T1 (hr)	2019-05-31
CN107602700A (zh)	2018-01-19
CA2836649C (en)	2020-06-23
TW202033559A (zh)	2020-09-16
US10208112B2 (en)	2019-02-19
AU2012258966B2 (en)	2017-03-09
ES2873837T3 (es)	2021-11-04
PT2710039T (pt)	2019-04-23
PL3495392T3 (pl)	2021-12-13
US20180215814A1 (en)	2018-08-02
AR118605A2 (es)	2021-10-20
TWI685505B (zh)	2020-02-21
AU2019226231B2 (en)	2021-06-03
EP2710039A2 (en)	2014-03-26
EP3875115A1 (en)	2021-09-08
EA201301295A1 (ru)	2014-04-30
BR122022012930B1 (pt)	2023-10-10
LT2710039T (lt)	2019-04-25
US10066009B2 (en)	2018-09-04
EP3495392A1 (en)	2019-06-12
CL2017001379A1 (es)	2017-12-29
JP6527563B2 (ja)	2019-06-05
TWI646111B (zh)	2019-01-01
NZ733060A (en)	2022-08-26
EP3662932B1 (en)	2021-04-07
MX2019008185A (es)	2019-09-09
CN107586338A (zh)	2018-01-16
CA2836649A1 (en)	2012-11-29
HUE055505T2 (hu)	2021-11-29
US10179809B2 (en)	2019-01-15
RS58621B1 (sr)	2019-05-31
PL3662932T3 (pl)	2021-09-06
NO2022029I1 (no)	2022-07-08
PH12018500521A1 (en)	2019-04-15
HUS2200031I1 (hu)	2022-07-28
EA039905B1 (ru)	2022-03-25
HUE054437T2 (hu)	2021-09-28
CL2013003336A1 (es)	2014-06-06
KR102128627B1 (ko)	2020-06-30
US11111289B2 (en)	2021-09-07
RS62306B1 (sr)	2021-09-30
AP2013007259A0 (en)	2013-11-30
JP6282584B2 (ja)	2018-02-21
SMT202100526T1 (it)	2021-11-12
CA3079978A1 (en)	2012-11-29
IL268464A (en)	2019-09-26
AR123876A2 (es)	2023-01-18
ES2715001T3 (es)	2019-05-31
MX370749B (es)	2019-12-20
MX2019015745A (es)	2020-02-13
EP2710039A4 (en)	2014-11-19
LTC3495392I2 (da)	2024-12-10
CY1124515T1 (el)	2022-07-22
CY1124209T1 (el)	2022-05-27
WO2012162243A2 (en)	2012-11-29
KR20140042819A (ko)	2014-04-07
US20120294797A1 (en)	2012-11-22
SMT201900293T1 (it)	2019-07-11
CN108373502B (zh)	2022-03-22
TWI692485B (zh)	2020-05-01
LTPA2022511I1 (da)	2022-07-11
US20190211085A1 (en)	2019-07-11
FR22C1032I1 (fr)	2022-09-09
SMT202100274T1 (it)	2021-07-12
TW201811835A (zh)	2018-04-01
TW201936642A (zh)	2019-09-16
IL270382B (en)	2020-11-30
AU2019226231A1 (en)	2019-09-26
RS61793B1 (sr)	2021-06-30
AR086516A1 (es)	2013-12-18
LT3495392T (lt)	2021-09-27
NZ717570A (en)	2018-09-28
ES2893073T3 (es)	2022-02-07
PH12013502405A1 (en)	2014-02-10
MX2013013535A (es)	2015-08-20
US20170174754A1 (en)	2017-06-22
JP2018038391A (ja)	2018-03-15
SG194938A1 (en)	2013-12-30
DK2710039T3 (da)	2019-04-01
LUC00270I2 (da)	2025-04-25
EA201592042A1 (ru)	2016-03-31
FR22C1032I2 (fr)	2023-06-02
PL2710039T3 (pl)	2019-07-31
NZ618637A (en)	2016-03-31
US10214582B2 (en)	2019-02-26
TR201904088T4 (tr)	2019-05-21
IL229431A0 (en)	2014-01-30
AU2017203890A1 (en)	2017-06-29
EP3495392B1 (en)	2021-08-18
IL268464B (en)	2020-10-29
CN108373502A (zh)	2018-08-07
WO2012162243A3 (en)	2013-01-17
US20240174738A1 (en)	2024-05-30
ZA201308637B (en)	2022-11-30
PT3662932T (pt)	2021-05-14
CN107586338B (zh)	2021-09-17
EP4115905A1 (en)	2023-01-11
AU2012258966C1 (en)	2022-02-03
US9745373B2 (en)	2017-08-29
PE20141787A1 (es)	2014-12-07
US20180215815A1 (en)	2018-08-02
TWI719869B (zh)	2021-02-21
CL2018001452A1 (es)	2018-08-10
SI3495392T1 (sl)	2021-11-30
AU2017203890B2 (en)	2019-06-06
CN107602700B (zh)	2021-12-17
DK3495392T3 (da)	2021-09-13
EP3662932A1 (en)	2020-06-10
IL261927B (en)	2019-11-28
EA031065B1 (ru)	2018-11-30
CN103748111B (zh)	2018-04-27
HRP20211395T1 (hr)	2021-12-10
US20180215813A1 (en)	2018-08-02
NL301181I1 (da)	2022-06-15
NL301181I2 (nl)	2022-11-24
CN103748111A (zh)	2014-04-23
PE20180502A1 (es)	2018-03-09
JP2014517699A (ja)	2014-07-24
CN108424452A (zh)	2018-08-21
TW201300419A (zh)	2013-01-01
SG10201604040PA (en)	2016-07-28
CN108424452B (zh)	2021-08-03
US10533048B2 (en)	2020-01-14
PH12013502405B1 (en)	2018-11-07
CA3080000A1 (en)	2012-11-29
SI2710039T1 (sl)	2019-05-31
PT3495392T (pt)	2021-09-22
SI3662932T1 (sl)	2021-08-31
CO6870005A2 (es)	2014-02-20
HUE044062T2 (hu)	2019-09-30
US20190092842A1 (en)	2019-03-28
HRP20210777T1 (hr)	2021-06-25
IL261927A (en)	2018-10-31
US20180215816A1 (en)	2018-08-02
US10189895B2 (en)	2019-01-29

Publication	Publication Date	Title
CY2022019I1 (el)	2023-01-05	Συνθεσεις αντι-cgrp και χρησεις αυτων
HUS2200031I1 (hu)	2022-07-28	Anti-CGRP készítmények és alkalmazásuk
DK3366143T3 (da)	2025-01-27	Probiotiske sammensætninger og fremgangsmåder
DK2794654T3 (da)	2019-08-05	Anti-phf-tau-antistoffer og deres anvendelser
DK2763665T3 (da)	2019-11-18	Antimikrobielle sammensætninger og fremgangsmåder til anvendelse deraf
BR112013023776A2 (pt)	2016-12-06	composição e abertura vedada com selante
BR112014010450A2 (pt)	2017-04-18	composição e método
EP2762504A4 (en)	2015-05-27	WATER- AND OIL-REPELLING COMPOSITION
DK2745849T3 (da)	2022-10-31	Polydeoxyribonukleotidsammensætning og anvendelser deraf
DK2704744T3 (da)	2019-07-15	Komplementfaktor-b-analoger og anvendelser deraf
BR112012029669A2 (pt)	2016-08-02	composição e método
BR112014010860A2 (pt)	2017-05-02	composição e método
DK2672837T4 (da)	2022-09-26	Ernæringssammensætning og anvendelser deraf
EP2702030A4 (en)	2014-09-10	COMPOSITIONS AND METHODS
BR112014007779A2 (pt)	2017-04-11	método e composição
BR112013008812A2 (pt)	2016-06-28	composição e método
EP2749168A4 (en)	2015-01-14	PLASTERIC COMPOSITION AND ITS USE
BR112013019707A2 (pt)	2017-03-21	métodos e composições antinematóides
BR112013013441A2 (pt)	2016-10-11	composição de adesivo-engomadura e métodos relacionados